Target intelligence / Profile preview

Immunoglobulin kappa variable 2D-30 (IGKV2D-30)

Target
IGKV2D-30
Molecular classification
Immunoglobulin variable region, Antibody variable domain, Other
01

Overview

Immunoglobulin kappa variable 2D-30 (IGKV2D-30) encodes the variable region of the kappa light chain of immunoglobulins (antibodies), which are glycoproteins produced by B lymphocytes[1][3][5][4]. The variable domain of this protein forms part of the antigen-binding site of antibodies, pairing with a heavy chain variable region to determine antigen specificity[1][7][3]. IGKV2D-30 is classified as a functional variable (V) gene within the distal cluster of the kappa light chain locus on chromosome 2p11.2[5][3]. Through V-J genomic rearrangement (a process known as V(D)J recombination), this segment combines with others to generate antibody diversity essential for adaptive immunity[1][3][8]. IGKV2D-30 itself is not a therapeutic target or disease driver; instead, it is part of the vast pool of antibody gene segments whose differential use affects immune repertoire diversity[1][5][3]. Variability at this locus can influence immune responses and has been implicated broadly in predisposition to infection, autoimmunity, and cancer through its role in antibody generation, but no direct drug interactions, biomarker status, or specific safety concerns are reported for this sequence itself[3][5][8].

Other names
IGKV2D-30Immunoglobulin kappa variable 2D-30IGKV2D30A1KV230KVD30
02

Biological functions

Antigen bindingImmune responseV(D)J recombination (for receptor diversity)Humoral immunity
03

Disease associations

Other (no direct association as a target; immunoglobulin variability contributes generally to infection, autoimmunity, cancer, but not as a primary disease driver)

Beyond the preview

Go deeper on Immunoglobulin kappa variable 2D-30 (IGKV2D-30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 2D-30 (IGKV2D-30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call